In 2019, Felix Baldauf-Lenschen joined Creative Destruction Lab with little more than just a hypothesis. Today, Altis Labs is developing AI-based endpoints for cancer clinical trials and has raised US$25M in Series A financing.
CDL's mission is to enhance the commercialization of science for the betterment of humankind #BuildSomethingMassive

